FDA submitted a proposed information collection to OMB for Paperwork Reduction Act review regarding formal hearing administrative procedures and practices.
CDC seeks public comment on a proposed Management Information System for Comprehensive Cancer Control Programs that will conduct annual key informant interviews and biennial surveys to monitor program outcomes.
CDC seeks public comment through [date] on the Expanding PrEP in Communities of Color (EPICC) data collection effort, which supports shared decision-making training and evaluation for preexposure prophylaxis providers serving diverse populations.
CDC seeks public comment on a data collection for mChoice, a research study testing tailored provider training and adherence support to improve PrEP uptake among young men who have sex with men in high-priority settings.
DEA issues temporary scheduling order placing 7-hydroxymitragynine above a specified threshold in Schedule I, subjecting manufacturers, distributors, importers, exporters, and researchers to Schedule I controlled substance regulations and penalties.
The Drug Enforcement Administration announces temporary scheduling of mitragynine pseudoindoxyl, MGM-15, and MGM-16 as Schedule I controlled substances, restricting manufacturing, distribution, possession, and research activities.
NIH requests 60-day public comment on proposed data collection for citizen science and crowdsourcing projects under Paperwork Reduction Act review; deadline is 60 days from publication.
The ATF is withdrawing its direct final rule on licensee "eZ Check" verification for transfers that was published May 6, 2026, in response to adverse comments.
ATF proposes amending NFA registration requirements to exempt manufacturers from registering firearms made for U.S. Government contracts and allow late registration if those firearms fall out of contract.
FDA corrects contact information for the Expedited Investigational New Drug Pilot Program docket, which solicits public input on shortening timelines from drug identification to first-in-human clinical trials.
Tell Bizmoon what your business does and we'll cut the Federal Register down to what actually matters.
Every rule is broken into specific to-dos with calendar dates.
We tell you which parts of your business each rule actually touches.
After healthcare come the capital-heavy sectors: trade, transportation, energy, and finance. If you operate in one of them, the volume of change is relentless.
No legal jargon. Read the impact in two sentences.
Email + dashboard pings the moment something changes.
